Back in 2017, the World Health Organization (WHO) published a report claiming that 10.5 percent of medications supplied in poor and middle-income nations, including India, are substandard, posing a major threat to patient safety and potentially leading to additional health issues. Manufacturing of critical commodities like drugs, needs a stringent quality control in the whole process starting from procurement of the raw material to delivery of the end –product. Non-compliance with the stipulated quality control procedures often leads to production of substandard drugs. Thus, affordable, accessible, and quality medicines in India is the need of the hour. This is where Unifaith Biotech comes in.
Head Quartered in the Capital of India, Unifaith Biotech is a burgeoning pharmaceutical organisation that delivers high quality critical care medicines across India. According to Mr. R.K. Dewan, Managing Director, Unifaith Biotech, “We are actively involved in the marketing of tested and certified pharmaceutical drugs pan-India, meeting the demand of quality and affordable healthcare products without any delay in supply through our channel distribution which is backed by a strong network of distributors and medical representatives pan India.”
Stringent quality control
When it comes to a life-or-death situation, the
quality of the drugs should not be compromised. Knowing this fact, Unifaith Biotech is managing its products with due vigilance. “The prime objective of the company is to offer the latest products to the medical fraternity to treat the ailing population and provide a better quality of life,” says R.K. Dewan. Starting with ingredient procurement, the company guarantees that hygienic and high-quality components are obtained for the formulation of their goods from genuine and reputable market suppliers. To offer high-quality products, the firm employs WHO-GMP certified plants only with modern production technologies and R&D setups for comprehensive quality control procedures.
Unifaith Biotech mainly focuses to provide medicines for the treatment of chronic diseases at a fast pace covering all regions across India. The company covers three major range of therapy - anti-infectives, Gastroenterology, and Oncology.
In the anti-infectives segment, the company provides Monobactams, Carbapenems, Higher Cephalosporins, Lincosamides, Macrolides, and various DCGI approved combination drugs combating resistance.
The gastro-range of the company comprises hepato-protective Range like Octreotide Injection, Terlipressin injection, L-Ornithine-L-Aspartate, Master antioxidant Glutathione injection which plays a pivotal role in the treatment of Hepatic Disorders such as Hepatitis and alcoholic fatty liver.
The prime objective of the company is to offer the latest products to the medical fraternity to treat the ailing population and provide a better quality of life
In the Oncology segment, the company aims to provide anti-cancer drugs like Pegylated Doxorubicin, Paclitaxel inj 260/100/30, Gemcitabine 1000/200, LAsparaginase, Trastuzumab etc.
Unifaith Biotech is actively transforming itself with the latest market trends. Today, the company has successfully adopted digitalization to uncover new patterns of working to increase efficacy and diversify employees’ skills.
In the future, the company wishes to establish its footprints in the untapped market of India. The company is actively working to install WHO/EUGMP approved manufacturing facility in the country. Within the coming 10 years, Unifaith Biotech believes in about enlisting itself as one of the top pharmaceutical companies in India.
.jpg "Overcoming the Hurdles of Scaling a Startup")
We use cookies to ensure you get the best experience on our website. Read more...
